These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 10544712)
1. [Recommendations for the drug therapy of diabetes type 2. Treatment of associated vascular risk factors. French Agency for the Safety of Therapeutic Products]. Presse Med; 1999 Oct; 28(29):1584-9. PubMed ID: 10544712 [No Abstract] [Full Text] [Related]
2. Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trial. Mosenzon O; Raz I; Scirica BM; Hirshberg B; Stahre CI; Steg PG; Davidson J; Ohman P; Price DL; Frederich B; Udell JA; Braunwald E; Bhatt DL Diabetes Metab Res Rev; 2013 Jul; 29(5):417-26. PubMed ID: 23564755 [TBL] [Abstract][Full Text] [Related]
3. Tackling type 2 diabetes-associated cardiovascular and renal comorbidities: a key challenge for drug development. Adeghate EA; Kalász H; Al Jaberi S; Adeghate J; Tekes K Expert Opin Investig Drugs; 2021 Feb; 30(2):85-93. PubMed ID: 33327794 [No Abstract] [Full Text] [Related]
4. Drugs for type 2 diabetes mellitus: the imperative for cardiovascular outcome assessment. Gore MO; McGuire DK Diab Vasc Dis Res; 2012 Apr; 9(2):85-8. PubMed ID: 22496441 [No Abstract] [Full Text] [Related]
5. [Glitazone - mailing no 1. In response to DMW 49/2007]. Traut V Dtsch Med Wochenschr; 2008 Feb; 133(6):261; author reply 262-3. PubMed ID: 18236356 [No Abstract] [Full Text] [Related]
6. Incretins: cardiovascular safety and rationale for use. Kok A Cardiovasc J Afr; 2013 Mar; 24(2):46. PubMed ID: 23750348 [No Abstract] [Full Text] [Related]
7. Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes. Tandon N; Ali MK; Narayan KM Am J Cardiovasc Drugs; 2012 Feb; 12(1):7-22. PubMed ID: 22217193 [TBL] [Abstract][Full Text] [Related]
8. Cardiovascular trials and diabetes treatments: a regulatory maze. Matthews DR Diab Vasc Dis Res; 2012 Apr; 9(2):83-4. PubMed ID: 22419242 [No Abstract] [Full Text] [Related]
9. Cardiovascular safety evaluation in the development of new drugs for diabetes mellitus. Menon V; Lincoff AM Circulation; 2014 Jun; 129(25):2705-13. PubMed ID: 24958753 [No Abstract] [Full Text] [Related]
11. [Prevention of cardiovascular disease in type 2 diabetic patients]. Yokota C Nihon Rinsho; 2003 Jul; 61(7):1161-6. PubMed ID: 12877078 [TBL] [Abstract][Full Text] [Related]
12. Semaglutide Reduces CV Events in High-Risk Patients with Type 2 Diabetes Mellitus. Ebell MH Am Fam Physician; 2017 Mar; 95(6):396. PubMed ID: 28318215 [No Abstract] [Full Text] [Related]
13. [Can glitazones provide protection of the kidneys?]. Bonnet F Journ Annu Diabetol Hotel Dieu; 2007; ():77-84. PubMed ID: 18610759 [No Abstract] [Full Text] [Related]
14. Office and ambulatory pulse pressure--association with clinical characteristics and cardiovascular risk factors in normoalbuminuric patients with type 2 diabetes (ROADMAP study). Januszewicz A; Ritz E; Viberti G; Mimran A; Rabelink AJ; Rump LC; Ruilope LM; Katayama S; Ito S; Izzo JL; Haller H J Hum Hypertens; 2011 Nov; 25(11):679-85. PubMed ID: 21150933 [TBL] [Abstract][Full Text] [Related]
15. Assessing the cardiovascular safety of diabetes therapies. Goldfine AB N Engl J Med; 2008 Sep; 359(11):1092-5. PubMed ID: 18784098 [No Abstract] [Full Text] [Related]
16. Intensive glucose control in type 2 diabetes. Parashar A N Engl J Med; 2008 Oct; 359(14):1520; author reply 1520-1. PubMed ID: 18837128 [No Abstract] [Full Text] [Related]
17. Retinopathy progression in type 2 diabetes. Morita H; Nagai R N Engl J Med; 2010 Nov; 363(22):2171; author reply 2173-4. PubMed ID: 21105810 [No Abstract] [Full Text] [Related]